June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Characterization of HtrA1 Promoter in Patients with Exudative Age-Related Macular Degeneration
Author Affiliations & Notes
  • Daisuke Iejima
    National Inst of Sensory Organs, Tokyo Medical Center, Higashigaoka Meguro-Ku, Japan
  • Toru Noda
    Division of Ophthalmology, Tokyo Medical Center, Higashigaoka Meguro-Ku, Japan
  • Atsushi Mizota
    Department of Ophthalmology, Teikyo University School of Medicine, Tokyo, Japan
  • Takeshi Iwata
    National Inst of Sensory Organs, Tokyo Medical Center, Higashigaoka Meguro-Ku, Japan
  • Footnotes
    Commercial Relationships Daisuke Iejima, None; Toru Noda, None; Atsushi Mizota, None; Takeshi Iwata, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 317. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daisuke Iejima, Toru Noda, Atsushi Mizota, Takeshi Iwata; Characterization of HtrA1 Promoter in Patients with Exudative Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):317.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness in the elderly. The dry form is more common and accounts for about 85~90% of AMD patients in US, while Japanese AMD patients predominantly progress to wet-form or polypoidal choroidal vasculopathy (PCV). Recent studies have shown HtrA1, a serine protease gene, as major risk factor for wet form AMD (DeWan et al., Science, 2006). Furthermore, we reported that Japanese typical wet form AMD patients show significant association with ARMS2/HtrA1 (rs10490924: p=4.1x10-14, OR=4.16) (Goto, Akahori et al., JOBDI, 2009). The purpose of study is to characterize promoter function of ARMS2 and HtrA1 genes in wet-form AMD.

Methods: Human peripheral blood was obtained from controls (cataract patient: CAT, 228 case) and Wet-AMD (226 case) patients. Genome DNA was extracted from peripheral blood samples using Magtration System 8Lx and 10Kb of promoter region containing ARMS2 gene was sequenced using ABI 3130 Genetic analyzer. ARMS2 and HtrA1 promoter activity was measured by luciferase assay (Dual-Glo Luciferase assay system, Promega, WI). Double strand DNA probe was designed based on the wild-type and mutant sequence and Electrophoresis Mobility Shift Assay (EMSA) (LightShift Chemiluminescent EMSA kit, Thermo Fisher Scientific, MA) was performed. The same probe was used to isolate binding transcription factors and to determine the peptide sequence using liquid chromatography-mass spectrometry (LC-MS/MS, LCQ DECA XP plus, Thermo Fisher Scientific, MA).

Results: The promoter sequence experiment showed that a great number of AMD patients had specific in/del mutation in 3.8 Kb upstream of HtrA1 gene. 2~3-fold increase of promoter activity was observed in in/del HtrA1 promoter compared to wild-type sequence. Furthermore, we detected in/del specific binding factors using EMSA and LC-MS/MS. These results suggest that Htra1 gene expression is influenced by transcription factor specifically binding to this region.

Conclusions: Human HtrA1 expression is enhanced by AMD specific in/del mutation in the promoter region of HtrA1 gene. Specific transcription factor, which likely to be involved in this enhancement was isolated and peptide sequence determined.

Keywords: 412 age-related macular degeneration • 739 transcription factors • 533 gene/expression  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.